Skip directly to search Skip directly to A to Z list Skip directly to navigation Skip directly to page options Skip directly to site content

Human Genome Epidemiology Literature Finder|Home|PHGKB

Human Genome Epidemiology Literature Finder


Last data update: Jun 1, 2023. (Total: 217488Documents)
   dataset        GWAS Only
Filtered By:

Previous    

Records 1 - 8 (of 8 Records)

Query Trace: Colorectal Neoplasms and CYP2A6[original query]
Novel markers of susceptibility to carcinogens in diet: associations with colorectal cancer.
Toxicology 2002 12 181-182 83-7.
Sweeney Carol, Coles Brian F, Nowell Susan, Lang Nicholas P, Kadlubar Fred
A pharmacogenetic study to investigate the role of dietary carcinogens in the etiology of colorectal cancer.
Carcinogenesis 2002 Nov 23 (11): 1839-49.
Sachse Christoph, Smith Gillian, Wilkie Murray J V, Barrett Jennifer H, Waxman Robin, Sullivan Frank, Forman David, Bishop D Timothy, Wolf C Roland,
A comprehensive analysis of phase I and phase II metabolism gene polymorphisms and risk of colorectal cancer.
Pharmacogenetics and genomics 2005 Aug 15 (8): 535-46.
Landi Stefano, Gemignani Federica, Moreno Victor, Gioia-Patricola Lydie, Chabrier Amélie, Guino Elisabeth, Navarro Matilde, de Oca Javier, Capellà Gabriel, Canzian Federico,
A Phase II study of clinical outcomes of 3-week cycles of irinotecan and S-1 in patients with previously untreated metastatic colorectal cancer: influence of the UGT1A1 and CYP2A6 polymorphisms on clinical activity.
Oncology 2012 82 (5): 5.
Choi YH, Kim TW, Kim KP, Lee SS, Hong YS, Ryu MH, Lee JL, Chang HM, Ryoo BY, Kim HS, Shin JG, Kang YK
Phase I clinical and pharmacokinetic/pharmacogenetic study of a triplet regimen of S-1/irinotecan/oxaliplatin in patients with metastatic colorectal or gastric cancer.
Cancer chemotherapy and pharmacology 2013 Nov 72 (5): 953-64.
Park Sook Ryun, Hong Yong Sang, Lim Hyeong-Seok, Seong Moon-Woo, Kong Sun-Young, Kim Sun Young, Park Young-Iee, Jung Kyung H
S-1 plus irinotecan and oxaliplatin for the first-line treatment of patients with metastatic colorectal cancer: a prospective phase II study and pharmacogenetic analysis.
British journal of cancer 2013 Sep 109 (6): 1420-7.
Kim S Y, S Hong Y, K Shim E, Kong S-Y, Shin A, Baek J Y, Jung K
[Validation of genetic polymorphisms associated to the toxicity of chemotherapy in colorectal cancer patients].
Farmacia hospitalaria : órgano oficial de expresión científica de la Sociedad Española de Farmacia Hospitalaria 0 38 (4): 283-90.
Cortejoso L, García M I, García-Alfonso P, Grávalos C, Robles L, González-Haba E, Sanjurjo M, López-Fernández L
Effects of polymorphic cytochrome P450 2A6 genotypes on chemoprevention against colorectal tumors in single Japanese cohort using daily low-dose aspirin: insights into future personalized treatments.
Journal of pharmaceutical health care and sciences 2021 7 7 (1): 26.
Yamazaki Hiroshi, Shimizu Makiko, Otani Takahiro, Mizugaki Ami, Mure Kanae, Suzuki Sadao, Ishikawa Hide
TOP